PRTA

Prothena Corporation plc is a clinical-stage biotechnology company headquartered in Dublin, Ireland, specializing in the discovery and development of novel therapeutics for severe, life-threatening diseases. The company boasts a promising pipeline targeting neurodegenerative disorders linked to protein misfolding, including Alzheimer's disease, thereby addressing significant unmet medical needs. By leveraging cutting-edge scientific research and a robust intellectual property portfolio, Prothena is well-positioned to become a leader in the biopharmaceutical sector, with the potential to deliver transformative treatments that enhance patient outcomes globally.